FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Labeling Options for Medical Device Symbols

[ Price : $8.95]

Two CDRH officials say that a new final rule on using symbols in medical device labeling gives manufacturers more options.

Comments on Quality Metrics Technical Guidance

[ Price : $8.95]

Five stakeholders provide comments and suggestions to FDA on a draft guidance on quality metrics technical conformance.

Duke Center Sets Medical Device Priorities

[ Price : $8.95]

Duke Universitys National Evaluation System for health Technology says its new coordinating center is to implement a national syst...

Concern Over FDA Medical Reviewer Revolving Door

[ Price : $8.95]

Researchers say they are concerned about the number of FDA medical reviewers who leave the agency to work for industry.

FDA Regulatory Review Period for Ionsys is 4,835 Days

[ Price : $8.95]

Federal Register Notice: FDA determines that 4,835 days is the regulatory review period for a Medicines Company NDA for Ionsys (fe...

Senators Want Mylan DoJ Probe

[ Price : $8.95]

Three senators ask the Justice Department to investigate whether Mylan deliberately misclassified its EpiPen as a non-innovator dr...

80% of Chinese Trial Data Fabricated: SFDA Report

[ Price : $8.95]

A one-year study by Chinese drug regulators finds massive fabrication of clinical trials data for drugs awaiting marketing approva...

FDA, Athersys Agree on Special Protocol for Cell Therapy

[ Price : $8.95]

FDA and Athersys reach agreement on a special protocol assessment for the design and planned analysis of a Phase 3 clinical trial ...

FDA Updates Expedited Access Pathway Web Site

[ Price : $8.95]

FDA adds two Expedited Access Program Data Development Plan examples to its Web site to give formatting suggestions to sponsors.

FDA Accepts BLA for Romosozumab in Osteoporosis

[ Price : $8.95]

FDA accepts for review an Amgen and UCB BLA for romosozumab, an investigational monoclonal antibody for treating osteoporosis in p...